Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial †
Titel:
Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial †
Auteur:
Oakman, C. Francis, P.A. Crown, J. Quinaux, E. Buyse, M. De Azambuja, E. Margeli Vila, M. Andersson, M. Nordenskjöld, B. Jakesz, R. Thürlimann, B. Gutiérrez, J. Harvey, V. Punzalan, L. Dell'Orto, P. Larsimont, D. Steinberg, I. Gelber, R.D. Piccart-Gebhart, M. Viale, G. Di Leo, A.